Joan (Huaqiong) Shen is the founder and CEO of NeuShen Therapeutics.

With wealthy global R&D experiences, Joan has a track record of success as a pharma executive. Before founding NeuShen Therapeutics, she served as head of R&D and CEO of I-Mab Biopharma. During her tenure, I-Mab was successfully listed on Nasdaq and formed a global collaboration with AbbVie for a CD-47 compound, Lemzoparlimab. Prior to I-Mab, Joan was the head of development of Janssen Pharmaceutical Company of J&J China where she led to multiple successful NDA/BLA approvals by China NMPA. She also built the largest clinical team among China’s domestic pharmas and led clinical trials in Australia, US, and China as the chief medical officer (CMO) of Hengrui Pharmaceutical.

Joan is a physician certified by the American Board of Psychiatry and Neurology. She holds a PhD in life science from Indiana University School of Medicine where she also completed her clinical residency training and three postdoctoral trainings in endocrinology, psychopharmacology, and clinical pharmacology. In the US, she was the clinical lead for CNS drug development at Eli Lilly & Co, Wyeth, and Pfizer, with increasing responsibilities.

She is currently a guest professor at Beijing University. Previously she served as an adjunctive professor of Indiana University School of Medicine.

Joan was selected by Endpoints News as one of the 20 women in Biopharma R&D in 2021. She was listed in Forbes’ Top 50 Women in Tech in China in 2021. She was named "Woman Leader of the Year” by Bay-Helix in 2022.